The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease

NCT01847313 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Diabetic Kidney Disease

Interventions

DRUG: Liraglutide

Sponsor

Karl Neff

Collaborators

[object Object]